{"id":68232,"date":"2026-06-15T21:56:51","date_gmt":"2026-06-15T13:56:51","guid":{"rendered":"https:\/\/flcube.com\/?p=68232"},"modified":"2026-06-15T21:56:53","modified_gmt":"2026-06-15T13:56:53","slug":"harbour-biomed-wins-20-2-million-patent-verdict-against-amgen-in-delaware-court","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68232","title":{"rendered":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Harbour BioMed (<a href=\"https:\/\/www.google.com\/finance\/quote\/2142:HKG\">HKG: 2142<\/a>)<\/strong> announced that a <strong>jury in the U.S. District Court for the District of Delaware<\/strong> has issued a <strong>decisive verdict<\/strong> in favor of the company in a <strong>patent infringement lawsuit<\/strong> originally filed against <strong>Amgen and its subsidiary Teneobio, Inc.<\/strong> (collectively &#8220;Amgen&#8221;) in <strong>2021<\/strong>. The jury awarded <strong>$20,203,704 in damages<\/strong>\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen&#8217;s infringement of Harbour&#8217;s antibody discovery platform patents was <strong>willful<\/strong>, potentially enabling treble damages up to <strong>$60.6 million<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-legal-proceedings-summary\" class=\"wp-block-heading\">Legal Proceedings Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Court<\/strong><\/td><td>U.S. District Court for the District of Delaware<\/td><\/tr><tr><td><strong>Case Filed<\/strong><\/td><td>2021<\/td><\/tr><tr><td><strong>Trial Duration<\/strong><\/td><td>June 8\u201315, 2026<\/td><\/tr><tr><td><strong>Defendants<\/strong><\/td><td>Amgen Inc. and Teneobio, Inc.<\/td><\/tr><tr><td><strong>Patents at Issue<\/strong><\/td><td>Grosveld patents covering Harbour&#8217;s antibody discovery platform<\/td><\/tr><tr><td><strong>Inventor<\/strong><\/td><td>Professor Frank Grosveld (Harbour Antibodies founder)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-jury-verdict-details\" class=\"wp-block-heading\">Jury Verdict Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Finding<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>Patent Infringement<\/strong><\/td><td>Amgen found to have infringed Grosveld patents<\/td><\/tr><tr><td><strong>Willfulness<\/strong><\/td><td>Infringement determined to be willful<\/td><\/tr><tr><td><strong>Patent Validity<\/strong><\/td><td>All asserted patents upheld as valid<\/td><\/tr><tr><td><strong>Compensatory Damages<\/strong><\/td><td>$20,203,704 (full amount requested)<\/td><\/tr><tr><td><strong>Enhanced Damages Potential<\/strong><\/td><td>Up to treble damages ($60.6 million total) possible<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-amp-intellectual-property\" class=\"wp-block-heading\">Technology &amp; Intellectual Property<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> Antibody discovery platform developed by Professor Frank Grosveld<\/li>\n\n\n\n<li><strong>Company Structure:<\/strong> Harbour Antibodies (inventor entity) is a member company of Harbour BioMed<\/li>\n\n\n\n<li><strong>Patent Scope:<\/strong> Multiple patents protecting core antibody discovery technology<\/li>\n\n\n\n<li><strong>Commercial Significance:<\/strong> Foundational IP for Harbour&#8217;s entire therapeutic pipeline<\/li>\n\n\n\n<li><strong>Competitive Impact:<\/strong> Validates Harbour&#8217;s proprietary position in antibody engineering<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<h3 id=\"h-for-harbour-biomed\" class=\"wp-block-heading\">For Harbour BioMed<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IP Validation:<\/strong> Court confirmation of patent strength and validity<\/li>\n\n\n\n<li><strong>Financial Impact:<\/strong> Immediate $20.2M award with potential for $60.6M total<\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Enhanced competitive moat around antibody discovery platform<\/li>\n\n\n\n<li><strong>Licensing Leverage:<\/strong> Strengthened position for future partnership negotiations<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-for-amgen-teneobio\" class=\"wp-block-heading\">For Amgen\/Teneobio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Financial Exposure:<\/strong> Potential liability up to $60.6M including enhanced damages<\/li>\n\n\n\n<li><strong>Operational Impact:<\/strong> May require technology redesign or licensing arrangements<\/li>\n\n\n\n<li><strong>Reputational Risk:<\/strong> Willful infringement finding damages corporate reputation<\/li>\n\n\n\n<li><strong>Strategic Setback:<\/strong> Disruption to Teneobio&#8217;s antibody development programs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-industry-impact\" class=\"wp-block-heading\">Market Context &amp; Industry Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Antibody Discovery Market:<\/strong> Highly competitive space with significant commercial stakes<\/li>\n\n\n\n<li><strong>Chinese Biotech IP:<\/strong> Demonstrates Chinese companies&#8217; ability to enforce global IP rights<\/li>\n\n\n\n<li><strong>Cross-Border Litigation:<\/strong> Successful prosecution of U.S. patent claims by Chinese entity<\/li>\n\n\n\n<li><strong>Precedent Setting:<\/strong> May influence future antibody platform disputes and licensing practices<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-legal-process\" class=\"wp-block-heading\">Next Steps &amp; Legal Process<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enhanced Damages Motion:<\/strong> Harbour to file request for treble damages based on willful infringement finding<\/li>\n\n\n\n<li><strong>Court Decision:<\/strong> Judge to determine whether to grant enhanced damages and final award amount<\/li>\n\n\n\n<li><strong>Appeal Timeline:<\/strong> Amgen likely to appeal verdict, potentially extending legal process 12-24 months<\/li>\n\n\n\n<li><strong>Enforcement:<\/strong> Harbour to pursue collection of damages pending any appeal outcomes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-impact-assessment\" class=\"wp-block-heading\">Financial Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Scenario<\/th><th>Damages Award<\/th><th>Probability<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Base Award<\/strong><\/td><td>$20.2 million<\/td><td>Certain (jury verdict)<\/td><td>Immediate cash infusion<\/td><\/tr><tr><td><strong>Enhanced Damages<\/strong><\/td><td>Up to $60.6 million<\/td><td>High (willful finding)<\/td><td>Significant financial windfall<\/td><\/tr><tr><td><strong>Settlement<\/strong><\/td><td>Undisclosed amount<\/td><td>Possible post-verdict<\/td><td>Expedited resolution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-broader-industry-significance\" class=\"wp-block-heading\">Broader Industry Significance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This verdict represents a <strong>watershed moment for Chinese biotechnology companies<\/strong> asserting intellectual property rights in U.S. courts. The successful outcome validates Harbour BioMed&#8217;s investment in foundational antibody discovery technology and demonstrates that Chinese innovators can effectively protect their IP against major global pharmaceutical competitors.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding legal proceedings, financial awards, and strategic implications. Actual results may differ due to appeals, judicial discretion on enhanced damages, and other legal uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500086_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026061500086_c.\"><\/object><a id=\"wp-block-file--media-abde8a99-38cc-4b23-b2aa-43ddbf71394e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500086_c.pdf\">2026061500086_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026061500086_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-abde8a99-38cc-4b23-b2aa-43ddbf71394e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,61],"tags":[190,916,73],"class_list":["post-68232","post","type-post","status-publish","format-standard","hentry","category-company","category-legal-ip","tag-harbour-biomed","tag-hkg-2142","tag-patents"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively &quot;Amgen&quot;) in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen&#039;s infringement of Harbour&#039;s antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68232\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court\" \/>\n<meta property=\"og:description\" content=\"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively &quot;Amgen&quot;) in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen&#039;s infringement of Harbour&#039;s antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68232\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-15T13:56:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-15T13:56:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court\",\"datePublished\":\"2026-06-15T13:56:51+00:00\",\"dateModified\":\"2026-06-15T13:56:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232\"},\"wordCount\":543,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Harbour BioMed\",\"HKG: 2142\",\"Patents\"],\"articleSection\":[\"Company\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68232#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68232\",\"name\":\"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-15T13:56:51+00:00\",\"dateModified\":\"2026-06-15T13:56:53+00:00\",\"description\":\"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively \\\"Amgen\\\") in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen's infringement of Harbour's antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68232\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68232#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court - Insight, China&#039;s Pharmaceutical Industry","description":"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively \"Amgen\") in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen's infringement of Harbour's antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68232","og_locale":"en_US","og_type":"article","og_title":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court","og_description":"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively \"Amgen\") in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen's infringement of Harbour's antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.","og_url":"https:\/\/flcube.com\/?p=68232","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-15T13:56:51+00:00","article_modified_time":"2026-06-15T13:56:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68232#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68232"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court","datePublished":"2026-06-15T13:56:51+00:00","dateModified":"2026-06-15T13:56:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68232"},"wordCount":543,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Harbour BioMed","HKG: 2142","Patents"],"articleSection":["Company","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68232#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68232","url":"https:\/\/flcube.com\/?p=68232","name":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-15T13:56:51+00:00","dateModified":"2026-06-15T13:56:53+00:00","description":"Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the District of Delaware has issued a decisive verdict in favor of the company in a patent infringement lawsuit originally filed against Amgen and its subsidiary Teneobio, Inc. (collectively \"Amgen\") in 2021. The jury awarded $20,203,704 in damages\u2014the full amount sought by Harbour BioMed\u2014and found that Amgen's infringement of Harbour's antibody discovery platform patents was willful, potentially enabling treble damages up to $60.6 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68232#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68232"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68232#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68232"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68232\/revisions"}],"predecessor-version":[{"id":68234,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68232\/revisions\/68234"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}